JCI Insight (Jul 2023)

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement

  • Christopher Nelke,
  • Christina B. Schroeter,
  • Frauke Stascheit,
  • Niklas Huntemann,
  • Marc Pawlitzki,
  • Alice Willison,
  • Saskia Räuber,
  • Nico Melzer,
  • Ute Distler,
  • Stefan Tenzer,
  • Kai Stühler,
  • Andreas Roos,
  • Andreas Meisel,
  • Sven G. Meuth,
  • Tobias Ruck

Journal volume & issue
Vol. 8, no. 13

Abstract

Read online

Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis (MG). However, a deeper understanding of complement modulation in the human system is required to improve treatment responses and identify off-target effects shaping long-term outcomes. For this reason, we studied a cohort of patients with MG treated with either eculizumab or azathioprine as well as treatment-naive patients using a combined proteomics and metabolomics approach. This strategy validated known effects of eculizumab on the terminal complement cascade. Beyond that, eculizumab modulated the serum proteometabolome as distinct pathways were altered in eculizumab-treated patients, including the oxidative stress response, mitogen-activated protein kinase signaling, and lipid metabolism with particular emphasis on arachidonic acid signaling. We detected reduced levels of arachidonate 5-lipoxygenase (ALOX5) and leukotriene A4 in eculizumab-treated patients. Mechanistically, ligation of the C5a receptor (C5aR) is needed for ALOX5 metabolism and generation of downstream leukotrienes. As eculizumab prevents cleavage of C5 into C5a, decreased engagement of C5aR may inhibit ALOX5-mediated synthesis of pro-inflammatory leukotrienes. These findings indicate distinct off-target effects induced by eculizumab, illuminating potential mechanisms of action that may be harnessed to improve treatment outcomes.

Keywords